Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.


Results 21-30 of 46 (Search time: 0.005 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2008Relationship between animal models and clinical research: using mucositis as a practical exampleGibson, R.; Bowen, J.; Keefe, D.
2008Use of project teams in preclinical developmentKeefe, D.; Bowen, J.; Gibson, R.
2010Matrix metalloproteinases play a pivotal role in the development of alimentary tract mucositisAl-Dasooqi, N.; Gibson, R.; Bowen, J.; Logan, R.; Stringer, A.; Keefe, D.; Sydney Cancer Conference (2010 : Sydney, New South Wales)
2007A novel animal model to investigate fractionated radiotherapy-induced alimentary mucositis: the role of apoptosis p53 nuclear factor-kappa B COX-1 and COX-2Yeoh, A.; Gibson, R.; Yeoh, E.; Bowen, J.; Stringer, A.; Giam, K.; Keefe, D.
2010Irinotecan-induced mucositis encompasses changes in intestinal and colonic cell kinetics and this is associated with altered extracellular matrix component expressionAl-Dasooqi, N.; Bowen, J.; Gibson, R.; Logan, R.; Stringer, A.; Keefe, D.; International MASCC/ISOO Symposium (2010 : Vancouver, Canada)
2006Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damageBowen, J.; Gibson, R.; Cummins, A.; Keefe, D.
2015Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot studyBowen, J.; White, I.; Smith, L.; Tsykin, A.; Kristaly, K.; Thompson, S.; Karapetis, C.; Tan, H.; Game, P.; Irvine, T.; Hussey, D.; Watson, D.; Keefe, D.
2007Role of p53 in irinotecan-induced intestinal cell death and mucosal damageBowen, J.; Gibson, R.; Stringer, A.; Chan, T.; Prabowo, A.; Cummins, A.; Keefe, D.
2017Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analysesCampbell, J.; Stephenson, M.; Bateman, E.; Peters, M.; Keefe, D.; Bowen, J.
2014Apoptosis, proliferation and inflammation are improved after treatment with the new selective glp-2 receptor agonist, elsiglutide, in a rat model of irinotecan-induced mucositisMayo, B.; Stringer, A.; Bateman, E.; Bowen, J.; Wignall, A.; Wozniak, B.; White, I.; Pietra, C.; Cantoreggi, S.; Keefe, D.; COSA's 41st Annual Scientific Meeting. Joining Forces - Accelerating Progress (02 Dec 2014 - 04 Dec 2014 : Melbourne, Vic.)